The Effect of Film Thickness on Thermal Aerosol Generation

Myers, Dan J.; Timmons, Ryan; Lu, Amy T.; Hale, Ron; Soni, Pravin; Rabinowitz, Joshua D.

doi:10.1007/s11095-006-9153-8

Cited by 10 publications

(4 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The effect of temperature 77 , initial film thickness 78 and energy 79 on the condensation aerosol was previously studied. The method was successfully used to make ibuprofen and indomethacin nanoparticles for inhalation 80,81 .…”

Section: Accepted Manuscriptmentioning

confidence: 99%

Inhalable nanoparticulate powders for respiratory delivery

Muralidharan

Malapit

Mallory

et al. 2015

Nanomedicine: Nanotechnology, Biology and Medicine

184

123

View full text Add to dashboard Cite

show abstract

Section: Accepted Manuscriptmentioning

confidence: 99%

Inhalable nanoparticulate powders for respiratory delivery

Muralidharan

Malapit

Mallory

et al. 2015

Nanomedicine: Nanotechnology, Biology and Medicine

184

123

View full text Add to dashboard Cite

show abstract

“…Vaporized drug resublimates into distinct aerosolized particles within a respirable size range, to be subsequently entrained by the airflow. Size distribution of the resublimated particles is controlled by the airflow velocity over the vaporizing compound (96). Even though the device locally generates high temperatures, it was shown that the peak wet bulb temperature of the outlet stream of 39.9 ±0.1°C, determined in a worst-case scenario setup, is well below the recommended standard of 50°C (97).…”

Section: Staccatomentioning

confidence: 99%

Devices for Dry Powder Drug Delivery to the Lung

2015

View full text Add to dashboard Cite

Abstract. Dry powder inhalers (DPIs) are an important and increasingly investigated method of modern therapy for a growing number of respiratory diseases. DPIs are a promising option for certain patient populations, and may help to overcome several limitations that are associated with other types of inhalation delivery systems (e.g., accuracy and reproducibility of the dose delivered, compliance and adherence issues, or environmental aspects). Today, more than 20 different dry powder inhalers are on the market to deliver active pharmaceutical ingredients (APIs) for local and/or systemic therapy. Depending on the mechanism of deagglomeration, aerosolization, dose metering accuracy, and the interpatient variability, dry powder inhalers demonstrate varying performance levels. During development, manufacturers focus on improving aspects characteristic of their specific DPI devices, depending on the intended type of application and any particular requirements associated with it. With the wide variety of applications related to specific APIs, there exists a range of different devices with distinct features. In addition to the routinely used multi-use DPIs, several single-use disposable devices are under development or already approved. The recent introduction of disposable devices will expand the range of possible applications for use by including agents such as vaccines, analgesics, or even rescue medications. This review article discusses the performance and advantages of recently approved dry powder inhalers as well as disposable single-use inhalers that are currently under development.

show abstract

“…7 In brief, loxapine was solubilized in an organic solvent and spray coated onto stainless steel foils. The solvent was allowed to evaporate to form a crystalline coating of loxapine.…”

Section: Loxapine Coatingmentioning

confidence: 99%